BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2771 related articles for article (PubMed ID: 33716082)

  • 21. Cetuximab enhances the anti-tumor function of macrophages in an IL-6 dependent manner.
    Zhao Y; Liu X; Huo M; Wang Y; Li Y; Xu N; Zhu H
    Life Sci; 2021 Feb; 267():118953. PubMed ID: 33359746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-200c/PAI-2 promotes the progression of triple negative breast cancer via M1/M2 polarization induction of macrophage.
    Meng Z; Zhang R; Wang Y; Zhu G; Jin T; Li C; Zhang S
    Int Immunopharmacol; 2020 Apr; 81():106028. PubMed ID: 31801690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
    Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
    J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk.
    Li H; Yang P; Wang J; Zhang J; Ma Q; Jiang Y; Wu Y; Han T; Xiang D
    J Hematol Oncol; 2022 Jan; 15(1):2. PubMed ID: 34991659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 26. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
    He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
    Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
    Ju X; Zhang H; Zhou Z; Chen M; Wang Q
    Exp Cell Res; 2020 Nov; 396(2):112315. PubMed ID: 33031808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nano formulated Resveratrol inhibits PD-L1 in oral cancer cells by deregulating the association between tumor associated macrophages and cancer associated fibroblasts through IL-6/JAK2/STAT3 signaling axis.
    Pradhan R; Paul S; Acharya SS; Sinha S; Dash SR; Kundu CN
    J Nutr Biochem; 2024 Mar; 125():109568. PubMed ID: 38185347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression.
    Liu Q; Yang C; Wang S; Shi D; Wei C; Song J; Lin X; Dou R; Bai J; Xiang Z; Huang S; Liu K; Xiong B
    Cell Commun Signal; 2020 Mar; 18(1):51. PubMed ID: 32228612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
    Cavalcante RS; Ishikawa U; Silva ES; Silva-Júnior AA; Araújo AA; Cruz LJ; Chan AB; de Araújo Júnior RF
    Br J Pharmacol; 2021 Jun; 178(11):2284-2304. PubMed ID: 33434950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple-negative breast cancer influences a mixed M1/M2 macrophage phenotype associated with tumor aggressiveness.
    Pe KCS; Saetung R; Yodsurang V; Chaotham C; Suppipat K; Chanvorachote P; Tawinwung S
    PLoS One; 2022; 17(8):e0273044. PubMed ID: 35960749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Apatinib Suppressed Macrophage-Mediated Malignant Behavior of Hepatocellular Carcinoma Cells via Modulation of VEGFR2/STAT3/PD-L1 Signaling].
    Yin T; Fu CB; Wu DD; Nie L; Chen H; Wang Y
    Mol Biol (Mosk); 2023; 57(4):706-708. PubMed ID: 37528791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dihydroartemisinin Prevents Progression and Metastasis of Head and Neck Squamous Cell Carcinoma by Inhibiting Polarization of Macrophages in Tumor Microenvironment.
    Chen R; Lu X; Li Z; Sun Y; He Z; Li X
    Onco Targets Ther; 2020; 13():3375-3387. PubMed ID: 32425545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
    Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 139.